This Medudy course is a conference report for physicians on the topic of “AUA Key Highlights 2026.”
Prof. Dr. Axel S. Merseburger, Director of the Department of Urology at the Lübeck Campus of the University Medical Center Schleswig-Holstein, will summarize key highlights from the studies presented at the conference.
This presentation will cover the results of the U.S. Phase II ARASEC study, which evaluated the efficacy and safety of darolutamide plus ADT in U.S. patients with mHSPC, as well as the expanded efficacy and safety analysis from the Phase IIIPOTOMAC study, which investigated the combination of durvalumab plus BCG in BCG-naive patients with high-risk non-muscle-invasive bladder cancer.
By the end of this conference report, you will know:
- Some of the highlights of AUA 2026
- The most important takeaways from the studies presented
- The expert's conclusion on the studies presented
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
